NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Masitinib for treating locally advanced
or metastatic pancreatic cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1.   Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No equalities issues were identified during consultation. At the scoping workshop, it was raised that masitinib may provide additional benefit to patients who find it difficult to travel to their nearest cancer centre because it is an oral drug and may be given at home. However, it is expected that the UK marketing authorisation will specify that masitinib should be given in combination with gemcitabine, which is administered intravenously, so patients receiving masitinib will still have to attend hospital to receive their treatment. Therefore, this does not represent an equalities issue.

2.   What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
No potential equalities issues have been identified that would need to be addressed by Committee.

3.   Has any change to the draft scope been agreed to highlight potential equality issues?
It was agreed that no changes to the draft scope were required to highlight any equality issues.

Technology Appraisals: Scoping
Equality impact assessment for the appraisal of masitinib for treating locally advanced or metastatic pancreatic cancer
Issue date: September 2013   1 of 2

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
	No additional stakeholders relating to potential equality issues were identified during the scoping process.

Approved by Associate Director (name): Janet Robertson …………
Date: 13 September 2013

Technology Appraisals: Scoping
Equality impact assessment for the appraisal of masitinib for treating locally advanced or metastatic pancreatic cancer
Issue date: September 2013   2 of 2